Cytosorbents Corp

Listed Company

CTSOCIK 0001175151NasdaqNon-AcceleratedSmaller ReportingSurgical & Medical Instruments & ApparatusDelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-8.20M

Total Assets

$44.18M

Equity

$5.90M

Shares Out

62.79M

Op. Cash Flow

$-12.38M

CTSO$0.39−63.06% · past yearDBEQ Basic

Daily closing prices

Business

CytoSorbents Corporation is a medical device company that develops and commercializes blood purification technologies based on biocompatible, porous polymer beads to remove toxic substances from blood in critical care and cardiac surgery settings. The company's lead product, CytoSorb, is approved in the European Union and distributed in more than 70 countries; the company is pursuing FDA approval for DrugSorb-ATR, an investigational antithrombotic removal system for perioperative bleeding in cardiothoracic surgery. Additional products include ECOS-300CY for ex vivo organ perfusion in transplant, VetResQ for animal health, and PuriFi, a hemoperfusion pump launched in the EU and select countries.

Summary from 10-K filed 2026-03-30

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenue, net	37	36	31	35	43
Cost of goods sold	11	11	9	14	11
Gross profit	26	25	22	21	32
Research and development, net of grant income	5	8	16	—	—
Selling, general and administrative	36	34	38	34	36
Restructuring	510,000	—	—	—	—
Total operating expenses	41	41	54	52	55
Loss from operations	−15	−16	−32	−32	−23
Interest expense, net	−3	−1	−157,891	132,597	28,007
Gain (loss) on foreign currency transactions	9	−4	2	−2	−3
Loss on abandoned patents	−559,000	−334,000	—	—	—
Total other income (expense), net	6	−6	2	−2	−3
Loss before benefit from income taxes	−9	−22	−30	−34	−25
Benefit from income taxes	401,000	2	813,739	1	736,003
Net loss	−8	−21	−29	−33	−25
Basic net loss per common share (in dollars per share)	−0.13	−0.38	−0.65	−0.75	−0.57
Diluted net loss per common share (in dollars per share)	−0.13	−0.38	−0.65	−0.75	−0.57
Weighted average number of shares of common stock outstanding, basic (in shares)	62	54	45	44	43
Weighted average number of shares of common stock outstanding, diluted (in shares)	62	54	45	44	43
Foreign currency translation adjustment, net of tax	−7	4	−2	2	2
Comprehensive loss	−15	−17	−31	−31	−22

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2024 2024-09-30	FY 2024 2024-06-30	FY 2024 2024-03-31
Cash and cash equivalents	6	3	—	—	—
Restricted cash, current	—	5	—	—	—
Accounts receivable, net of allowances of $164 and $158 at December 31, 2025 and 2024, respectively	8	7	—	—	—
Inventories - net	5	3	3	4	4
Prepaid expenses and other current assets	2	3	—	—	—
Total current assets	21	22	17	22	20
Property and equipment - net	8	9	—	—	—
Restricted cash	2	1	—	—	—
Right-of-use asset	11	12	—	—	—
Patents - net	3	4	—	—	—
Other assets	53,000	50,000	—	—	—
Total Assets	44	47	48	53	47
Accounts payable	3	3	—	—	—
Accrued expenses and other current liabilities	6	6	6	6	7
Lease liability - current portion	541,000	453,000	—	—	—
Total current liabilities	10	10	8	10	13
Lease liability, net of current portion	12	12	—	—	—
Long-term debt, net of debt discount	17	14	—	—	—
Total Liabilities	38	36	35	36	27
Commitments and Contingencies	—	—	—	—	—
Preferred Stock, Par Value $0.001, 5,000,000 shares authorized; no shares issued and outstanding at December 31, 2025 and 2024	—	—	—	—	—
Common Stock, Par Value $0.001, 100,000,000 shares authorized; and 62,804,305 and 54,830,146 shares issued and outstanding at December 31, 2025 and 2024, respectively	63,000	55,000	—	—	—
Additional paid-in capital	321	311	310	309	307
Accumulated other comprehensive income (loss)	−3	4	—	—	—
Accumulated deficit	−312	−304	−296	−294	−289
Total Stockholders' Equity	6	11	13	17	20
Total Liabilities and Stockholders' Equity	44	47	48	53	47

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−8	−21	—	—	—
Accrued final fee	—	111,000	42,857	—	—
Amortization of debt discount	820,000	265,000	564,356	249,008	398,035
Amortization of loan costs	—	116,000	—	—	—
Amortization of patents	262,000	235,000	—	—	—
Depreciation and amortization	1	1	1	882,621	731,578
Amortization of right-of-use asset	135,000	174,000	564,356	—	—
Write off of inventory	253,000	—	—	—	—
Bad debt expense	40,000	115,000	14,434	−8,354	−512
Write off of fixed assets	104,000	—	—	—	—
Foreign currency transaction (gains) losses	−9	4	−2	2	3
Stock-based compensation	3	4	4	3	4
Grants and accounts receivable	423,000	−2	−245,616	−1	420,578
Inventories	−3	500,000	183,273	945,352	−2
Prepaid expenses and other current assets	2	−1	1	−22,187	280,915
Other assets	2,000	1,000	−49	52,678	−135,857
Accounts payable and accrued expenses	−706,000	−2	2	−3	2
Net cash used in operating activities	−12	−14	−22	−28	−14
Purchases of property and equipment	−164,000	−284,000	−538,115	−6	−4
Disposal of property and equipment	76,000	—	—	—	—
Patent costs	−327,000	−385,000	−398,121	−368,211	−640,013
Net cash used in investing activities	−415,000	−669,000	−936,236	−6	−4
Proceeds from long-term debt	2	15	—	5	—
Repayment of long-term debt	—	−5	—	—	—
Payment of final fee	—	−150,000	—	—	—
Payment of loan costs	—	−698,000	—	—	—
Proceeds from rights offering, net	5	—	—	—	—
Cash for exercise of warrants, net	1	—	—	—	—
Equity contributions - net of fees incurred	—	179,000	14	−40,358	−90,000
Net cash provided by financing activities	9	9	14	5	715,199
Effect of exchange rates on cash	1	−85,000	−99,769	−262,924	−24,774
Net change in cash, cash equivalents, and restricted cash	−2	−6	−8	−30	−18
Cash paid during the year for interest	2	1	376,668	—	—
Warrants issued in connection with modification of long-term debt	627,000	691,000	—	—	—
Capital expenditures included in accounts payable	—	8,000	—	359,965	—
Settlement of accrued bonuses with restricted stock units	—	198,000	403,939	380,091	928,417

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Cytosorbents Corp's CIK number?

Cytosorbents Corp's SEC CIK number is 0001175151 (1175151). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Cytosorbents Corp's SEC filings?

All of Cytosorbents Corp's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did Cytosorbents Corp last report earnings?

Cytosorbents Corp (CTSO) most recently filed an earnings 8-K with the SEC on May 13, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0000929638-26-001834). This is Cytosorbents Corp's most recent earnings filing of record — not a forecast of its next earnings date.

What is Cytosorbents Corp's most recent earnings 8-K?

Cytosorbents Corp's latest earnings 8-K (Item 2.02) was filed May 13, 2026 under accession 0000929638-26-001834. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View Cytosorbents Corp's latest earnings 8-K →
Look up any company's CIK number →